Triple-negative breast cancer: present challenges and new perspectives.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature, limited treatment options, and poor patient outcomes.
• The absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 overexpression defines TNBC, contributing to its distinct biological behavior and therapeutic resistance.
• Understanding the molecular drivers of TNBC heterogeneity and its association with BRCA1 mutations is crucial for developing effective treatment strategies.

Purpose of the Study:

• To provide an overview of TNBC profiling, including expression signatures within functional genomic classifications.
• To highlight ongoing efforts in identifying novel therapeutic targets and bioimaging markers for TNBC.
• To emphasize the need for advanced analytical approaches to decipher TNBC complexity.

Main Methods:

• Review of current literature on TNBC molecular profiling and expression signatures.
• Analysis of combined 'omics' data to understand TNBC heterogeneity.
• Exploration of systems biology approaches for biomarker and target discovery.

Main Results:

• TNBC is characterized by complex aberrant molecular patterns contributing to its heterogeneity and aggressive progression.
• Current research focuses on expression signatures and functional genomic classification for TNBC.
• Identification of potential new therapy targets and bioimaging markers is an active area of investigation.

Conclusions:

• Advances in individualized TNBC treatment require a deeper understanding of molecular mechanisms, particularly phenotypic heterogeneity and BRCA1 mutation links.
• The complexity of TNBC necessitates multi-dimensional data collection and robust multivariate analysis.
• Innovative systems biology approaches are essential for discovering novel TNBC biomarkers and therapeutic targets.